RE:RE:RE:Shareholder valueThe stock has no pulse because the cannabis hype train has left the station and this business (like most normal ones) is being judged on what have you done for me lately.
LABS was never a stock that benefited from any of the hype appreciation when hype in cannabis was a thing, now that it's not, nothing will move the SP appreciably except for the pharma unicorn. We'll get a bump when we reach break even (or better) because that de-risks the going concern/cash issues.
A RS does nothing for the business except make it easier for it (and the financing houses) to make money in future share offerings while killing long suffering shareholders at the same time. If mgmt sees pharma success, then having 500e6 shares for a lead cannabis pharma participant will be peanuts given the market sizes. But if they want to do a RS, they need to do it only once the SP recovers to a level where it would make sense to.....like say a buck or two.